Thomson Reuters

Current Opinion in Investigational Drugs is a monthly publication covering all therapeutic areas, in recognition of the increasingly multi-disciplinary nature of modern drug discovery and development.

SUBJECT DIVISION

Six therapeutic areas are covered with each being featured in separate journal issues and covered twice yearly. The broad therapeutic categories and the specialist topics within each are as follows:

• Anti-infectives Antifungals and antiparasitics; antibacterials (b-lactams, glycopeptides and other agents); antibacterials (quinolones, macrolides and oxazolidinones); vaccines; antivirals (HIV); antivirals (non-HIV)
• Anti-inflammatory, immunologicals and biologicals Musculoskeletal; respiratory; dermatology; nervous system; transplantation
• Cardiovascular and renal Hypertension and renal failure; stroke and angina; arrhythmia and heart failure; antithrombotics; hemostasis and hematological diseases; atherosclerosis, hypercholesterolemia and heart disease
• Endocrine and metabolics Diabetes, reproductive endocrinology, hormone disorders, bone metabolism and obesity
• Central and peripheral nervous system Pain; neuro-urology and neurogastroenterology; neurodegenerative and cognitive disorders; affective/behavioral/personality disorders and substance abuse; neurology and neuroprotection; schizophrenia and psychosis
• Oncological Cell signaling modulators; cytotoxic drugs; immunotherapeutic drugs and monoclonal antibodies; protein therapeutics, including growth factors; gene therapy; antisense inhibitors

Each issue also contains a general paper and patent alerts section which covers all therapeutic areas.

SELECTION OF TOPICS TO BE REVIEWED

Section Editors, who are major authorities in the field, divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasized. Section Editors recommend reviews from authorities on each topic that they have selected. Submitted articles are peer reviewed before publication.

“Current Opinion in Investigational Drugs provides a unique review forum for the discussion of current developments in a wide range of therapeutic areas.”

EDITOR IN CHIEF, MICHAEL WILLIAMS, NORTHWESTERN UNIVERSITY MEDICAL SCHOOL, USA

With Current Opinion in Investigational Drugs, you can:

• Read critical reviews of selected areas of investigational drug research.
• Gain expert evaluation of selected drugs currently in clinical trials.
• Browse the most interesting papers and patents, annotated by experts.
  

Why choose Current Opinion in Investigational Drugs?

Peer reviewed by an internationally renowned editorial board, this superb title delivers to you the most important coverage on developments in all the therapeutic areas listed in the subject division.

The systematic approach of this journal ensures that you won't miss any recent developments related to your own area of research.

EACH ISSUE CONTAINS

Paper alerts
Expert commentary on a selection of recently published papers is provided.

Patent alerts
Brief commentaries on the scientific and/or commercial significance of new patents selected and written by experts within their respective fields. These are presented beside the patent abstract, published by Thomson Reuters.

Editorial overview
Short overviews in which an area of interest to the pharmaceutical industry is critically reviewed in the context of recent developments.

Reviews
Concise reviews in which authors present recent developments in their subject, emphasizing the aspects that, in their opinion, are most important. In addition, they provide short annotations to the cited papers that they consider to be the most interesting from all those published in their topic. Papers chosen by an author as being 'of special interest' or 'of outstanding interest' are clearly identified in the reference list at the end of each review. The reviews focus predominantly on investigational drugs, or the therapeutic/commercial applications of new discoveries.

Drug profiles
Expert commentary on the scientific and commercial potential of selected drugs in clinical trials are provided in each issue, in the form of drug profiles. A drug profile is a review of the available literature (scientific and commercial), including the authors opinion of the drug’s therapeutic and commercial potential. Further information on these drugs appears in Thomson Reuters' Investigational Drugs database (IDdb) and Thomson Pharma platform.

Annual indexes
In the last issue of each volume, cumulative indexes of contents, subjects and authors are provided.

Current Opinion in Investigational Drugs contains contributions from internationally recognized leaders in pharmaceutical R&D. All contributions are invited and peer-reviewed by an Editorial Board comprising of distinguished members of the scientific community.

EDITOR IN CHIEF

Michael Williams (USA)

CO-EDITORS

Stanley Crooke (USA)
Annette Doherty (UK)
William Hagmann (USA)
John Kemp (Germany)
Jacob J Plattner (USA)

PATENT EDITOR

Hermann AM Mucke (Austria)

SECTION EDITORS

Anti-infectives Robin Cooper (USA), Simon Croft (UK), Christian Hubschwerlen (Switzerland), Jeffrey H Toney (USA), Alan Johnson (UK), Barney Koszalka (USA), Nicholas Meanwell (USA), Rino Rappuoli (Italy)

Anti-inflammatory, Immunologicals and Biologicals Cynthia Darlington (New Zealand), David Howat (France), Randall Morris (USA), Neville Punchard (UK)

Cardiovascular and renal Frank Barone (USA), Tom Colatsky (USA), De-Zai Dai (China), Delvin Knight (USA), Brian Krause (USA), Keith E Suckling (UK), J Ruth Wu-Wong (USA)

Central and Peripheral Nervous System Mike Briley (France), Mike Crowell (USA), Robert Davis (USA), Steve England (UK), Peter Goadsby (UK), Clifford Woolf (USA), Mike Wyllie (UK), Stevin Zorn (USA)

Endocrine and Metabolics Bruno Allolio (Germany), Franklyn Bolander (USA), Joy Hinson (UK), Nigel Levens (USA), Terry Opgenorth (USA)

Oncological Suresh Ambudkar (USA), Andrew Dorr (USA), David Gewirtz (USA), Michael Lotze (USA), Alain Rolland (USA), Edward Sausville (USA), Ian Stratford (UK), Mario Sznol (USA), Paul Workman (UK)